PURPOSE:Patients requiring mechanical ventilation (MV) for >48 h after major heart surgery (MHS) are at a high risk of acquiring ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT). Most non-pharmacological interventions to prevent VAP in such patients are usually already implemented. The objective of this study was to evaluate the efficacy in preventing lower respiratory infections of antibiotics active against multidrug-resistant pathogens in this very high-risk population. METHODS: We performed a prospective randomized open-label study of MHSpatients requiring MV for >48 h. Patients were randomly allocated to one of two groups: the intervention group, which received a 3-day course of linezolid and meropenem, and the control group, which received the standard of care. The main outcome was the development of VAP or VAT. RESULTS: Overall, of the 78 patients included in the study, 40 were in the intervention group and 38 in the control group. Both groups were comparable. Data for the intervention and control groups respectively were as follows: VAP + VAT/1,000 days was 31.79 vs 64.78 (p = 0.03), median length of MV before the first episode of VAP or VAT 9 vs 4.5 days (p = 0.02). No significant differences were observed in median length of stay in the intensive care unit, median length of hospital stay, antibiotic use, Clostridium difficile infection, and overall mortality rate. We detected linezolid-resistant coagulase-negative and coagulase-positive staphylococci in the MHS intensive care unit after the study period. CONCLUSIONS: A pre-emptive approach with broad-spectrum antibiotics may be effective in reducing the incidence and delaying the onset of VAP + VAT after MHS. The ecological consequences have to be carefully evaluated in future trials.
RCT Entities:
PURPOSE:Patients requiring mechanical ventilation (MV) for >48 h after major heart surgery (MHS) are at a high risk of acquiring ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT). Most non-pharmacological interventions to prevent VAP in such patients are usually already implemented. The objective of this study was to evaluate the efficacy in preventing lower respiratory infections of antibiotics active against multidrug-resistant pathogens in this very high-risk population. METHODS: We performed a prospective randomized open-label study of MHSpatients requiring MV for >48 h. Patients were randomly allocated to one of two groups: the intervention group, which received a 3-day course of linezolid and meropenem, and the control group, which received the standard of care. The main outcome was the development of VAP or VAT. RESULTS: Overall, of the 78 patients included in the study, 40 were in the intervention group and 38 in the control group. Both groups were comparable. Data for the intervention and control groups respectively were as follows: VAP + VAT/1,000 days was 31.79 vs 64.78 (p = 0.03), median length of MV before the first episode of VAP or VAT 9 vs 4.5 days (p = 0.02). No significant differences were observed in median length of stay in the intensive care unit, median length of hospital stay, antibiotic use, Clostridium difficileinfection, and overall mortality rate. We detected linezolid-resistant coagulase-negative and coagulase-positive staphylococci in the MHS intensive care unit after the study period. CONCLUSIONS: A pre-emptive approach with broad-spectrum antibiotics may be effective in reducing the incidence and delaying the onset of VAP + VAT after MHS. The ecological consequences have to be carefully evaluated in future trials.
Authors: G Christopher Wood; Bradley A Boucher; Martin A Croce; Scott D Hanes; Vanessa L Herring; Timothy C Fabian Journal: Pharmacotherapy Date: 2002-08 Impact factor: 4.705
Authors: Emilio Bouza; Ana Pérez; Patricia Muñoz; M Jesús Pérez; Cristina Rincón; Carlos Sánchez; Pablo Martín-Rabadán; Mariano Riesgo Journal: Crit Care Med Date: 2003-07 Impact factor: 7.598
Authors: Maria Hernandez-Garcia; Monica Girona-Alarcon; Sara Bobillo-Perez; Mireia Urrea-Ayala; Anna Sole-Ribalta; Mònica Balaguer; Francisco-José Cambra; Iolanda Jordan Journal: PLoS One Date: 2022-07-14 Impact factor: 3.752
Authors: Jean-Louis Vincent; Matteo Bassetti; Bruno François; George Karam; Jean Chastre; Antoni Torres; Jason A Roberts; Fabio S Taccone; Jordi Rello; Thierry Calandra; Daniel De Backer; Tobias Welte; Massimo Antonelli Journal: Crit Care Date: 2016-05-17 Impact factor: 9.097